Kaleido Biosciences Inc (KLDO) is a clinical-stage healthcare company that is developing microbiome-based therapies to treat a range of diseases and conditions. The company's proprietary Microbiome Metabolic Therapies (MMT™) platform is designed to modulate the microbiome in a targeted and non-invasive manner to improve health outcomes.
As of market close on March 4, 2023, the current market capitalization for KLDO is approximately $149 million.
Kaleido Biosciences has several drug candidates in its pipeline, including treatments for liver disease and inflammatory bowel disease. The company has also recently entered into partnerships and collaborations with leading pharmaceutical companies to develop new therapies and expand its MMT™ platform.
Kaleido Biosciences has faced some challenges in recent years, including setbacks in clinical trials and difficulties in obtaining regulatory approval for its products. However, the company has recently implemented a strategic plan aimed at reducing costs, improving product offerings, and driving growth.
|
